StreetInsider.com News Articles

Vivos Therapeutics plans rights offering to raise capital

Thu, 11 Jun 2026 08:30:44 -0400

Vivos Therapeutics Inc. (NASDAQ: VVOS) announced its intent to file a registration statement with the Securities and Exchange Commission for a proposed rights offering that would distribute transferable subscription rights to shareholders as a dividend.

The medical device company expects to file the registration statement and distribute rights to shareholders 30 days after the SEC declares the statement effective. Each right would entitle holders to purchase one share of common stock at an exercise price of either $1.25 per share or 20% above the market price on the day before the record date, whichever is greater.

The rights would be exercisable for

Vivos Therapeutics plans rights offering to raise capital

Thu, 11 Jun 2026 08:30:44 -0400

The rights would be exercisable for

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Thu, 11 Jun 2026 08:30:00 -0400

LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders.

The Company currently expects to file a registration statement in connection

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Thu, 11 Jun 2026 08:30:00 -0400

The Company currently expects to file a registration statement in connection

Vivos partners with Florida cardiology group for sleep disorder treatment

Wed, 10 Jun 2026 09:04:13 -0400

Vivos Therapeutics Inc. (NASDAQ: VVOS) entered into a collaboration agreement with South Palm Cardiovascular Associates LLC to form AIM Florida LLC, a management services organization focused on treating sleep disorders in cardiovascular patients.

The partnership will address obstructive sleep apnea and insomnia diagnosis and treatment for approximately 30,000 patients of record at the Florida-based cardiology practice. Vivos expects to hold at least 80% of the membership interests in AIM Florida, with South Palm Cardiovascular Associates holding up to 20%.

The collaboration will initially focus on patients in Palm Beach County, Florida. The operating plan calls for establishing one Sleep Optimization Team capable

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Wed, 10 Jun 2026 09:03:00 -0400

LITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA") and insomnia, today announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC ("SPCVA"), a growing Florida-based cardiology practice with approximately 30,000 patients of record, to support the formation and operation of AIM Florida, LLC ("AIM Florida"), a physician-aligned management services organization intended to expand access to integrated diagnostic

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Wed, 10 Jun 2026 09:03:00 -0400

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Wed, 10 Jun 2026 09:03:00 -0400

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Wed, 10 Jun 2026 09:03:00 -0400

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Mon, 08 Jun 2026 13:39:17 -0400

LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.